Researchers at the Cira Foundation (Kyoto, Japan) have published an informative study** that highlights how defined culture conditions using Amsbio StemFit™ Basic03 medium coupled with a supportive matrix (iMatrix-511) contribute to controlling hiPSC behaviour and differentiation efficiency.
The Institute of Cancer Research (ICR) in London seeks to appoint a Group Leader in Cancer Stem Cell Biology to play a pivotal role in advancing our cutting-edge cancer research. The position will be based in newly-refurbished laboratory and office space at our Sutton campus within the Division of Cancer Biology. We welcome applications at both the Career Development Faculty and Career Faculty levels.
The Institute of Cancer Research (ICR) in London seeks to appoint a Group Leader in In Vivo Cancer Modelling to play a pivotal role in advancing our cutting-edge cancer research. The position is based at the newly established Centre for In Vivo Modelling (CIVM), part of the Division of Cancer Biology. We welcome applications at both the Career Development Faculty and Career Faculty levels.
Key Requirements
LONDON, UK – January 20, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for mOm Incubators Ltd (“mOm”) and is pleased to announce the placement of Daniel Green as Chief Operating Officer (COO).
Researchers' expectations of antibodies are changing—from "whether they can be used" to "whether they are stable enough, easy to engineer, and truly meet research needs."
Our strategy sets out to bring deeper mechanistic understanding at the molecular and cellular level to all stages of projects, from Idea to pre-clinical candidate.
In this role, you will define the vision and strategy for CRH early project enablement, establishing robust processes to select and advance promising targets into the drug discovery portfolio. You will lead and develop a matrixed team, guiding them to deliver clear go/nogo decisions through deep expertise in target feasibility and druggability.
This post represents an opportunity to join an exciting multipartner consortium in the ‘END2AMR’ project to help develop novel antimicrobials using high throughput transposon mutagenesis to help understand mechanisms of action, host susceptibility and resistance. The candidate will join the Webber group within the Quadram Institute and have opportunities to develop their skillset within a vibrant and supportive environment.